PDCD1 gene
Incyte’s Zynyz Secures FDA Approval for Anal Cancer After Previous Rejection
Incyte; Zynyz; retifanlimab; FDA approval; anal cancer; PD-1 inhibitor; first-line therapy; immunotherapy; clinical trial; POD1UM-303; combination chemotherapy
Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial
Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration
Akeso’s PD-1 inhibitor notches inaugural FDA nod for nasopharyngeal cancer
United States Food and Drug Administration, Approved, Akeso, Nasopharyngeal carcinoma, PDCD1 gene, Inhibitor, Akeso ‘s, Anniko
AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial
Rosnilimab, PD-1 agonist, rheumatoid arthritis, Phase 2b trial, immune modulation, AnaptysBio, autoimmune disease
Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor
Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts
Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG
Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda
Bristol Myers Squibb Marks Milestone with FDA Approval of Subcutaneous Opdivo Qvantig
Bristol Myers Squibb, Opdivo, subcutaneous administration, FDA approval, cancer treatment, immuno-oncology, PD-1 inhibitor.
FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression
PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab
FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression
FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval